Plain-English translation of NCT05229341 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is evaluating a new diagnostic test called DDMS-2 that analyzes genetic markers in tissue samples from thyroid nodules to help doctors determine if a nodule is cancerous. Right now, when doctors find a thyroid nodule, it can be hard to tell whether it's cancer or not — and many patients end up having unnecessary surgery. This test aims to give doctors a clearer answer so they can make better treatment decisions.
Many thyroid nodules are found to be 'indeterminate,' meaning doctors cannot tell from standard tests whether they are cancer or benign. This causes unnecessary anxiety and often leads to surgery even when the nodule isn't cancer. This medication aims to solve that problem by providing a more accurate genetic test that can help doctors avoid unnecessary procedures.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will undergo a needle biopsy of your thyroid nodule (which you may already be scheduled for). Your tissue sample will be analyzed using the new DDMS-2 test, and your medical records will be reviewed. The study team will then track how this test result affects your doctor's treatment decisions.
AI-generated summary from trial data · Jun 7, 2026 · Not medical advice
United States
Sponsor
City of Hope Medical Center
Collaborators
National Cancer Institute (NCI)
Enrollment target
~1,450 participants
Started
October 2021
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.